Confronto

Semaglutid vs. VK2735

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

910463-68-2

nessun dato

Peso molecolare

4113.6 g/mol

nessun dato

Emivita

165 h

nessun dato

Sequenza

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

nessun dato

Meccanismo d'azione

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Semaglutid	VK2735
Svizzera	Su prescrizione	—
Germania	Su prescrizione	Non approvato
Stati Uniti	Su prescrizione	Non approvato

Voci complete

Frequently asked questions

What is the difference between Semaglutid and VK2735?: Semaglutid is classified as "Metabolico", while VK2735 is classified as "Metabolico". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Semaglutid or VK2735?: The highest available evidence level is "RCT sull'uomo" for Semaglutid and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Semaglutid and VK2735 in Germany and the United States?: Germania: Semaglutid — Su prescrizione, VK2735 — Non approvato. Stati Uniti: Semaglutid — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Semaglutid

VK2735

Svizzera

Su prescrizione

—

Germania

Su prescrizione

Non approvato

Stati Uniti

Su prescrizione

Non approvato

Frequently asked questions

What is the difference between Semaglutid and VK2735?

Semaglutid is classified as "Metabolico", while VK2735 is classified as "Metabolico". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Semaglutid or VK2735?

The highest available evidence level is "RCT sull'uomo" for Semaglutid and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Semaglutid and VK2735 in Germany and the United States?

Germania: Semaglutid — Su prescrizione, VK2735 — Non approvato. Stati Uniti: Semaglutid — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.